Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Pralsetinib

fe2c9504-a682-53d2-af21-4ddc46531c9a · FDA Approved · targets RET

Pralsetinib

MeasuredReference

Pralsetinib targets RET, ERBB4_HER4, NTRK3. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RETERBB4_HER4NTRK3NTRK2EGFR

Top hallmarks

  • tumor promoting inflammation7.0k
  • proliferation4.7k
  • evading apoptosis4.4k

Top pathways disrupted

  • pi3k akt mtor signaling11.2k
  • apical junction11.1k
  • allograft rejection10.9k

Resistance landscape — Pralsetinib

MeasuredReference

10 known oncogenic variants exist on Pralsetinib's top targets — see detail for inhibition impact.

Open in new tab